Allarity announces dismissal of securities class action lawsuit

Allarity (ALLR) Therapeutics announced that the securities class action lawsuit in the United States District Court for the Southern District of New York referenced in the Company’s Form 10-Q filing on November 11, 2024, has been dismissed in whole against all defendants. The lawsuit, originally filed on September 13, 2024, alleged that false or misleading statements were made regarding the regulatory prospects of the Dovitinib New Drug Application and related matters. Allarity has consistently maintained that these claims were without merit. The case against all defendants has been dismissed with each party bearing its own legal costs and fees. No settlement or payment of any kind was made by the Company or any of its officers in connection with this dismissal.